Skip to main content
Erschienen in: Pediatric Nephrology 8/2022

10.01.2022 | Original Article

Benign and malignant proliferation in idiopathic nephrotic syndrome: a French cohort study

verfasst von: Clara Cébron, Astrid Godron-Dubrasquet, Nathalie Aladjidi, Gwenaelle Roussey, Olivia Boyer, Marina Avramescu, Veronique Baudouin, Joelle Terzic, Emma Allain-Launay, Frédéric Rieux-Laucat, Stéphane Decramer, Thomas Simon, Jérôme Harambat

Erschienen in: Pediatric Nephrology | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

There seems to be a possible link between nephrotic syndrome (NS) and lymphoproliferative syndrome, but it remains poorly understood.

Methods

This multicentric and retrospective study focuses on children, who developed idiopathic NS and malignant or benign proliferation between 2000 and 2021.

Results

Eleven patients were included, with a median age of 4 years. Only one had a steroid-resistant nephrotic syndrome (SRNS). The maintenance therapy before the proliferation was in majority tacrolimus or mycophenolate mofetil (MMF), but three patients did not receive treatments. The proliferation was mainly a Hodgkin’s lymphoma (45%) or a lymphoproliferative disease (36%), in a median time after the NS of two years. Viruses were found in seven cases (EBV in five cases and HHV-8 in two).

Conclusion

The association between proliferative syndrome and idiopathic NS may not be fortuitous, possibly with a common lymphocytic disturbance. Genetic analyses could improve the comprehension of these manifestations in the future.

Graphical abstract

A higher resolution version of the Graphical abstract is available as Supplementary information
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Dossier C, Jamin A, Deschênes G (2017) Idiopathic nephrotic syndrome: the EBV hypothesis. Pediatr Res 81:233–239CrossRef Dossier C, Jamin A, Deschênes G (2017) Idiopathic nephrotic syndrome: the EBV hypothesis. Pediatr Res 81:233–239CrossRef
2.
Zurück zum Zitat Kyrieleis HA, Löwik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, van den Heuvel BL, Wetzels JF, Levtchenko EN (2009) Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 4:1593–1600CrossRef Kyrieleis HA, Löwik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, van den Heuvel BL, Wetzels JF, Levtchenko EN (2009) Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 4:1593–1600CrossRef
3.
Zurück zum Zitat Rüth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ (2005) Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 147:202–207CrossRef Rüth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ (2005) Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 147:202–207CrossRef
4.
Zurück zum Zitat Farruggia P, Trizzino A, Maringhini S, Grigoli A, Sapia C, D’Alessandro M, Tropia S, D’Angelo P (2010) Hodgkin lymphoma and nephrotic syndrome in childhood. Indian J Pediatr 77:1147–1149CrossRef Farruggia P, Trizzino A, Maringhini S, Grigoli A, Sapia C, D’Alessandro M, Tropia S, D’Angelo P (2010) Hodgkin lymphoma and nephrotic syndrome in childhood. Indian J Pediatr 77:1147–1149CrossRef
5.
Zurück zum Zitat Stéphan JL, Deschênes G, Pérel Y, Bader-Meunier B, Brunat-Mentigny M, Lejars O, Lamagnères JP (1997) Nephrotic syndrome and Hodgkin disease in children: a report of five cases. Eur J Pediatr 156:239–242CrossRef Stéphan JL, Deschênes G, Pérel Y, Bader-Meunier B, Brunat-Mentigny M, Lejars O, Lamagnères JP (1997) Nephrotic syndrome and Hodgkin disease in children: a report of five cases. Eur J Pediatr 156:239–242CrossRef
6.
Zurück zum Zitat Audard V, Larousserie F, Grimbert P, Abtahi M, Sotto JJ, Delmer A, Boue F, Nochy D, Brousse N, Delarue R, Remy P, Ronco P, Sahali D, Lang P, Hermine O (2006) Minimal change nephrotic syndrome and classical Hodgkin’s lymphoma: report of 21 cases and review of the literature. Kidney Int 69:2251–2260CrossRef Audard V, Larousserie F, Grimbert P, Abtahi M, Sotto JJ, Delmer A, Boue F, Nochy D, Brousse N, Delarue R, Remy P, Ronco P, Sahali D, Lang P, Hermine O (2006) Minimal change nephrotic syndrome and classical Hodgkin’s lymphoma: report of 21 cases and review of the literature. Kidney Int 69:2251–2260CrossRef
8.
Zurück zum Zitat Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61–748CrossRef Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61–748CrossRef
9.
Zurück zum Zitat Dufek S, Cheshire C, Levine AP, Trompeter RS, Issler N, Stubbs M, Mozere M, Gupta S, Klootwijk E, Patel V, Hothi D, Waters A, Webb H, Tullus K, Jenkins L, Godinho L, Levtchenko E, Wetzels J, Knoers N, Teeninga N, Nauta J, Shalaby M, Eldesoky S, Kari JA, Thalgahagoda S, Ranawaka R, Abeyagunawardena A, Adeyemo A, Kristiansen M, Gbadegesin R, Webb NJ, Gale DP, Stanescu HC, Kleta R, Bockenhauer D (2019) Genetic identification of two novel loci associated with steroid-sensitive nephrotic syndrome. J Am Soc Nephrol 30:1375–1384CrossRef Dufek S, Cheshire C, Levine AP, Trompeter RS, Issler N, Stubbs M, Mozere M, Gupta S, Klootwijk E, Patel V, Hothi D, Waters A, Webb H, Tullus K, Jenkins L, Godinho L, Levtchenko E, Wetzels J, Knoers N, Teeninga N, Nauta J, Shalaby M, Eldesoky S, Kari JA, Thalgahagoda S, Ranawaka R, Abeyagunawardena A, Adeyemo A, Kristiansen M, Gbadegesin R, Webb NJ, Gale DP, Stanescu HC, Kleta R, Bockenhauer D (2019) Genetic identification of two novel loci associated with steroid-sensitive nephrotic syndrome. J Am Soc Nephrol 30:1375–1384CrossRef
10.
Zurück zum Zitat Sato M, Kamei K, Ogura M, Ishikura K, Ito S (2018) Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion. Clin Exp Nephrol 22:110–116CrossRef Sato M, Kamei K, Ogura M, Ishikura K, Ito S (2018) Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion. Clin Exp Nephrol 22:110–116CrossRef
11.
Zurück zum Zitat Dossier C, Sellier-Leclerc AL, Rousseau A, Michel Y, Gautheret-Dejean A, Englender M, Madhi F, Charbit M, Ulinski T, Simon T, Jacqz-Aigrain E, Deschênes G (2014) Prevalence of herpesviruses at onset of idiopathic nephrotic syndrome. Pediatr Nephrol 29:2325–2331CrossRef Dossier C, Sellier-Leclerc AL, Rousseau A, Michel Y, Gautheret-Dejean A, Englender M, Madhi F, Charbit M, Ulinski T, Simon T, Jacqz-Aigrain E, Deschênes G (2014) Prevalence of herpesviruses at onset of idiopathic nephrotic syndrome. Pediatr Nephrol 29:2325–2331CrossRef
12.
Zurück zum Zitat Jossen J, Chu J, Hotchkiss H, Wistinghausen B, Iyer K, Magid M, Kamath A, Roayaie S, Arnon R (2015) Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: a review. Pediatr Transplant 19:235–243CrossRef Jossen J, Chu J, Hotchkiss H, Wistinghausen B, Iyer K, Magid M, Kamath A, Roayaie S, Arnon R (2015) Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: a review. Pediatr Transplant 19:235–243CrossRef
13.
Zurück zum Zitat Taliaferro A, Samhouri Y, Rice J, Khan CM, Cillo JE (2021) Rare oral presentation of a mycophenolate mofetil-related other iatrogenic immunodeficiency-associated lymphoproliferative disorder (MMF-OIA-LPD) lesion: a case report and literature review. J Oral Maxillofac Surg 79:398–403CrossRef Taliaferro A, Samhouri Y, Rice J, Khan CM, Cillo JE (2021) Rare oral presentation of a mycophenolate mofetil-related other iatrogenic immunodeficiency-associated lymphoproliferative disorder (MMF-OIA-LPD) lesion: a case report and literature review. J Oral Maxillofac Surg 79:398–403CrossRef
14.
Zurück zum Zitat Crane GM, Powell H, Kostadinov R, Rocafort PT, Rifkin DE, Burger PC, Ambinder RF, Swinnen LJ, Borowitz MJ, Duffield AS (2015) Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget 6:33849–33866CrossRef Crane GM, Powell H, Kostadinov R, Rocafort PT, Rifkin DE, Burger PC, Ambinder RF, Swinnen LJ, Borowitz MJ, Duffield AS (2015) Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget 6:33849–33866CrossRef
15.
Zurück zum Zitat Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T (2016) Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Clin Nephrol 85:340–345CrossRef Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T (2016) Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Clin Nephrol 85:340–345CrossRef
16.
Zurück zum Zitat Boland BS, Widjaja CE, Banno A, Zhang B, Kim SH, Stoven S, Peterson MR, Jones MC, Su HI, Crowe SE, Bui JD, Ho SB, Okugawa Y, Goel A, Marietta EV, Khosroheidari M, Jepsen K, Aramburu J, López-Rodríguez C, Sandborn WJ, Murray JA, Harismendy O, Chang JT (2015) Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency. J Immunol 194:2551–2560CrossRef Boland BS, Widjaja CE, Banno A, Zhang B, Kim SH, Stoven S, Peterson MR, Jones MC, Su HI, Crowe SE, Bui JD, Ho SB, Okugawa Y, Goel A, Marietta EV, Khosroheidari M, Jepsen K, Aramburu J, López-Rodríguez C, Sandborn WJ, Murray JA, Harismendy O, Chang JT (2015) Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency. J Immunol 194:2551–2560CrossRef
17.
Zurück zum Zitat Go WY, Liu X, Roti MA, Liu F, Ho SN (2004) NFAT5/TonEBP mutant mice define osmotic stress as a critical feature of the lymphoid microenvironment. Proc Natl Acad Sci U S A 101:10673–10678CrossRef Go WY, Liu X, Roti MA, Liu F, Ho SN (2004) NFAT5/TonEBP mutant mice define osmotic stress as a critical feature of the lymphoid microenvironment. Proc Natl Acad Sci U S A 101:10673–10678CrossRef
18.
Zurück zum Zitat Lee N, Kim D, Kim WU (2019) Role of NFAT5 in the immune system and pathogenesis of autoimmune diseases. Front Immunol 10:270CrossRef Lee N, Kim D, Kim WU (2019) Role of NFAT5 in the immune system and pathogenesis of autoimmune diseases. Front Immunol 10:270CrossRef
19.
Zurück zum Zitat Chavarría-Smith J, Mitchell P, Ho A, Daugherty M, Vance R (2016) Functional and evolutionary analyses identify proteolysis as a general mechanism for NLRP1 inflammasome activation. PLoS Pathogens 12:e1006052CrossRef Chavarría-Smith J, Mitchell P, Ho A, Daugherty M, Vance R (2016) Functional and evolutionary analyses identify proteolysis as a general mechanism for NLRP1 inflammasome activation. PLoS Pathogens 12:e1006052CrossRef
20.
Zurück zum Zitat Institute of Medicine (US) and National Research Council (US) National Cancer Policy Board. Childhood cancer survivorship: improving care and quality of life. Hewitt M, Weiner SL, Simone JV, editors (2003) Washington (DC): National Academies Press (US) Institute of Medicine (US) and National Research Council (US) National Cancer Policy Board. Childhood cancer survivorship: improving care and quality of life. Hewitt M, Weiner SL, Simone JV, editors (2003) Washington (DC): National Academies Press (US)
Metadaten
Titel
Benign and malignant proliferation in idiopathic nephrotic syndrome: a French cohort study
verfasst von
Clara Cébron
Astrid Godron-Dubrasquet
Nathalie Aladjidi
Gwenaelle Roussey
Olivia Boyer
Marina Avramescu
Veronique Baudouin
Joelle Terzic
Emma Allain-Launay
Frédéric Rieux-Laucat
Stéphane Decramer
Thomas Simon
Jérôme Harambat
Publikationsdatum
10.01.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 8/2022
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-021-05386-0

Weitere Artikel der Ausgabe 8/2022

Pediatric Nephrology 8/2022 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.